Inspira geht Partnerschaft mit Glo-Med voor US-Vertrieb einem Investing.com

RA’ANANA, Israel – Inspira Technologies OXY BHN Ltd. (NASDAQ:IINN, IINNW), an Entwickler fortschrittlicher Lebenserhaltungstechnologie, which has a strategic partnership with Glo-Med Networks Inc. has developed. This partnership is a Glo-Med main partner for inspiration in the United States, with the development of the INSPIRA ART100 systems, one of the FDA for the Cardiopulmonary Bypass (CPB) Verfahren-zugelassene devices.

The analysis conducted in Florida will present an issue in the installation and handling of the INSPIRA ART100 Systems systems, with more efficient operations on comparable products. Glo-Med provides targeted advice, expert support and certified aftermarket services when partnered with Med-Stat Consulting Services, a national biomedical engineering services offering worldwide.

Joe Hayon, administrator and chairman of Inspira Technologies, has founded the Bedeutung der Vereinbarung for the market development of the innovative technologies of the unternehmens, which help us to start the Flaggschiff-Geräts INSPIRA ART and other products in Entwicklung.

Matus Knoblich, CEO of Glo-Med, said that the integration of the Vertriebsnetzes of Glo-Med with the high level of service of the medical state was a higher degree of substantiation and service within the industry, was the Wachstum of the Marke and the Nutzererfahrung of Inspira Technologies offered.

Inspira Technologies has developed the INSPIRA ART, a device that revolutionizes the mechanical stroke market with Augmented Respiration Technology. The INSPIRA ART was developed by patients with the display of the Blutsauerstoff level that is so high that a mechanical order of battle is created. There are few options left in the US$19 billion, 20 million patient market out there.

The INSPIRA ART100, the FDA 510(k)-certification for CPB-Verfahren is one of the extensive portfolios, including the INSPIRA ART500, the INSPIRA Cardi-ART, the VORTX orbiting Oxygen Delivery System and the HYLA blunt sensor if all goes well, everything in the Entwicklung is over and no longer such a spoilery of indulgence.

The information presented is based on a press conference by Inspira Technologies.

In other cases, Inspira Technologies has developed a new U.S. patent for the VORTX™ Blood Oxygenation Delivery System, a brand of INSPIRA™ ART devices. The INSPIRA™ ART100 System of the Unternehmens, the FDA 510(k)-Zulassung for the Einsatz in Cardiopulmonary Bypass-Verfahren hat, soll in führenden Krankenhäusern in the USA and Israel became effective.

Inspira Technologies has developed a clinical trial for its HYLA™ fire sensor, a device with real fire extinguishing water observations, in four quarters of 2024 with approval. The external device has a Bluttestein-richtung, one of the sensors installed at the factory, anfang 2025 a 510(k)-Antrag with the FDA application.

We have found the INSPIRA™ CART from the Unternehmens, which works for the Einsatz with the INSPIRA™ ART100 system, from the FDA listed. There is a first purchase for the pleasure of the INSPIRA™ ART100 system from Glo-Med Networks, Inc. developed. The third generation has developed a product with the INSPIRA™ ART (Gen 2) and the INSPIRA™ Cardi-ART, which has not previously been tested by humans or has been regulated.

These young studies are part of the fortlaufenden of inspiration, the medical technology can be used and patient care will be expanded. The company is certain of a direct action, which will bring in an amount of 1.65 million dollars for the Betriebskapital and everything else in the world. It is important that you end up on the beach, but the inspiration is focused on shifting risks and uncertainties.

InvestingPro Insights

Während Inspira Technologies (NASDAQ:IINN) has developed some interesting financial knowledge and experience with investment projects with its strategic analyses. Its internal market capitalization was US$25.72 million and was an active position as a small-cap actor in a broader Medizintechnology sector.

InvestenPro data look, the inspiration in the month and in the third month is a strong return verzeichnet hat, with a price trend of 13.93% bzw. 27.52%. This positive impetus is given to the strategic writing of the Unternehmens organization, wie de Vertriebsvereinbarung with Glo-Med Networks.

If you are sitting on the beach, you can do a single financial refinancing move on a beautiful hat. An InvestingPro tip pointing out that the outside company’s money was spent focused on the capital-intensive nature of the business and the marketing of the medical company with the INSPIRA ART100 system an obvious factor.

Another InvestingPro Tipp has her inspiration for more money as debt abroad. Because you want certain financial flexibility, you can expand your product portfolio and your market price.

For investors, who make such an analysis, InvestingPro offers 6 other tips for Inspira Technologies, one of the many financial benefits and market position of our third-party companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.